In fact, Turner et al., through a viability assay, showed that the breast cancer cell lines MDA-MB-134 and SUM44, which overexpress FGFR1 were resistant to 4-hydroxytamoxifen (4-OHT) [49]. This evidence concerns the gene FGFR1 and breast carcinoma.